Araştırma Makalesi

In silico analysis of biomarker potentials of miRNA-mediated ceRNAs in prostate cancer

Cilt: 45 Sayı: 4 13 Aralık 2018
PDF İndir

In silico analysis of biomarker potentials of miRNA-mediated ceRNAs in prostate cancer

Öz

Objective: The objective of this study is to define novel biomarkers for Prostate Cancer (PCa) via in silico analysis that takes PCa-specific miRNAs, finds their combinatorial target genes (potential ceRNAs), selects ones containing Transcribed Ultra Conserved Region (T-UCR) among them and potentiates their relevance with PCa.

Methods: Thirty-four miRNAs of which clinical relevances with PCa were proved experimentally were exported via miRWalk database.Using the ComiR database, 859 genes targeted by these 34 miRNAs simultaneously were identified. Genes with ComiR score above 0.911 were taken into account. Genes containing T-UCR and showing potential ceRNA activity were extracted. Among PCa-associated ceRNAs including T-UCR, we identified genes with significant expression differences between PCa and normal prostate tissue using the GEPIA database. The statistical evaluation of the association of NFAT5 and PTBP2 genes with PCa was performed by Spearman correlation test in GEPIA database.

Results: PCa-associated ceRNAs cross-matching with genes including T-UCR in their exonic regions were NFAT5, CLK3, PTBP2, CPEB4, MIPOL1 and TCF4. We identified genes with significant expression differences between PCa and normal prostate tissues among PCa-associated ceRNAs including T-UCR. According to this analysis, NFAT5 and PTBP2 genes were significantly less expressed in PCa than in normal prostate tissue while the others didn’t show any significant differential expression pattern. NFAT5 and PTBP2 genes were found to be significantly associated with PCa (p=0.000012; R=0.72).

Conclusion: All in all, this is the study associating NFAT5 and PTBP2 genes with PCa and giving them tumor suppressive potential for PCa. Still, larger and more comprehensive studies are needed on this issue.

Anahtar Kelimeler

Kaynakça

  1. 1. Yikilmaz TN, Öztürk E. Yüksek Riskli Prostat Kanserinde Radikal Prostatektomi/Radical Prostatectomy In High-Risk Prostate Cancer. Dicle Med J. 2016; 43 :419.
  2. 2. Saydam F, Değirmenci İ, Güneş HV. MicroRNAs and cancer. Dicle Med J. 2011; 38 :113-20.
  3. 3. Ergun S, Oztuzcu S. Oncocers: ceRNA-mediated cross-talk by sponging miRNAs in oncogenic pathways. Tumor Biol. 2015; 36 :3129-36.
  4. 4. Zhou J, Wang R, Zhang J, et al. Conserved expression of ultra-conserved noncoding RNA in mammalian nervous system. BBA-Gene Regul Mech. 2017; 1860 :1159-68.
  5. 5. Bodakçi MN, Bozkurt Y, Atar M, et al. The results of transrectal prostate biopsy in patients with low levels of prostate specific antigen. Dicle Med J. 2012; 39.
  6. 6. Dweep H, Gretz N. miRWalk2. 0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015; 12 :697-.
  7. 7. Coronnello C, Benos PV. ComiR: combinatorial microRNA target prediction tool. Nucleic Acids Res. 2013; 41(W1): W159-W64.
  8. 8. Bejerano G, Pheasant M, Makunin I, et al. Ultraconserved elements in the human genome. Science. 2004; 304(5675): 1321-5.

Ayrıntılar

Birincil Dil

Türkçe

Konular

-

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

13 Aralık 2018

Gönderilme Tarihi

15 Aralık 2018

Kabul Tarihi

27 Temmuz 2018

Yayımlandığı Sayı

Yıl 2018 Cilt: 45 Sayı: 4

Kaynak Göster

APA
Ergün, S. (2018). In silico analysis of biomarker potentials of miRNA-mediated ceRNAs in prostate cancer. Dicle Medical Journal, 45(4), 415-429. https://doi.org/10.5798/dicletip.497900
AMA
1.Ergün S. In silico analysis of biomarker potentials of miRNA-mediated ceRNAs in prostate cancer. diclemedj. 2018;45(4):415-429. doi:10.5798/dicletip.497900
Chicago
Ergün, Sercan. 2018. “In silico analysis of biomarker potentials of miRNA-mediated ceRNAs in prostate cancer”. Dicle Medical Journal 45 (4): 415-29. https://doi.org/10.5798/dicletip.497900.
EndNote
Ergün S (01 Aralık 2018) In silico analysis of biomarker potentials of miRNA-mediated ceRNAs in prostate cancer. Dicle Medical Journal 45 4 415–429.
IEEE
[1]S. Ergün, “In silico analysis of biomarker potentials of miRNA-mediated ceRNAs in prostate cancer”, diclemedj, c. 45, sy 4, ss. 415–429, Ara. 2018, doi: 10.5798/dicletip.497900.
ISNAD
Ergün, Sercan. “In silico analysis of biomarker potentials of miRNA-mediated ceRNAs in prostate cancer”. Dicle Medical Journal 45/4 (01 Aralık 2018): 415-429. https://doi.org/10.5798/dicletip.497900.
JAMA
1.Ergün S. In silico analysis of biomarker potentials of miRNA-mediated ceRNAs in prostate cancer. diclemedj. 2018;45:415–429.
MLA
Ergün, Sercan. “In silico analysis of biomarker potentials of miRNA-mediated ceRNAs in prostate cancer”. Dicle Medical Journal, c. 45, sy 4, Aralık 2018, ss. 415-29, doi:10.5798/dicletip.497900.
Vancouver
1.Sercan Ergün. In silico analysis of biomarker potentials of miRNA-mediated ceRNAs in prostate cancer. diclemedj. 01 Aralık 2018;45(4):415-29. doi:10.5798/dicletip.497900

Cited By